In Reply We agree with the comments made by Viansone and colleagues and appreciate that they have brought to our attention the results of Liu et al,¹ who have shown similar results to ours.² In the study by Liu et al,¹ patients with colon cancer with at least 1 low-affinity allele (FCGR2A-131R) had improved overall survival compared with patients with only high-binding alleles (FCGR2A-131H). Although we did not see this same result for the FCGR2A-131H/R alleles, we did observe that patients who had only the low-binding allele (158F) for FCGR3A had a better prognosis than patients with 1 or more high-binding alleles (FCG3A-158V) among patients with breast cancer included in the chemotherapy arm of NSABP clinical trial B-31. The prognostic effect associated with FCGR2A in colon cancer and FCGR3A in breast cancer may be a result of the different types of immune reactions that result from breast and colon cancer, although this explanation is purely speculative.

作为答复我们同意 Viansone 及其同事的意见，并感谢他们让我们注意到 Liu 等人¹的结果，他们与我们的结果相似。²在 Liu 等人的研究中，与仅具有高结合等位基因 ( FCGR2A -131H)的患者相比， ¹名具有至少 1 个低亲和力等位基因 ( FCGR2A -131R) 的结肠癌患者的总生存期有所提高。虽然我们没有看到FCGR2A -131H/R 等位基因的相同结果，但我们确实观察到，只有FCGR3A的低结合等位基因 (158F) 的患者比具有 1 个或更多高结合等位基因的患者预后更好。FCG3A-158V）在 NSABP 临床试验 B-31 化疗组中的乳腺癌患者中。与结肠癌中的FCGR2A和乳腺癌中的FCGR3A相关的预后效应可能是由乳腺癌和结肠癌引起的不同类型的免疫反应的结果，尽管这种解释纯粹是推测性的。